Medicines For Europe Recommends Changes To EU Pharmaceutical Legislation
Prioritizes Digitalization Of Regulatory Framework And Incentivizing Manufacturing Investments
Medicines for Europe has offered several suggestions to re-evaluate the EU’s pharmaceutical legislation, including moves to allow off-patent competition from day one of exclusivity expiry as well as to ensure a competitive and balanced single market for multi-source medicines. The European off-patent industry body also discussed access issues, unmet medical needs and incentives in its feedback.
